Last reviewed 2026-05-25 · How we verify

Tanadopa (DOCARPAMINE)

Phase 2 active Small molecule ✓ Verified May 2026

Tanadopa (generic name: DOCARPAMINE) is a Catecholamine drug. It is currently in Phase 2 development.

Tanadopa works by increasing the levels of norepinephrine in the brain, which can help to improve alertness and attention.

Tanadopa is a small molecule with the synonyms DOCARPAMINA, DOCARPAMINE, TA-870, and TANADOPA. Its modality is a small molecule.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DOCARPAMINE
Drug class	Catecholamine
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of Tanadopa like a key that unlocks more of a certain chemical messenger in the brain called norepinephrine. This chemical helps us feel more alert and focused, and Tanadopa helps to turn up the volume on this signal. As a result, people taking Tanadopa may feel more awake and alert, but the exact effects can vary depending on the individual and the condition being treated.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tanadopa CI brief — competitive landscape report
Tanadopa updates RSS · CI watch RSS

Frequently asked questions about Tanadopa

What is Tanadopa?

Tanadopa (DOCARPAMINE) is a Catecholamine drug.

How does Tanadopa work?

Tanadopa works by increasing the levels of norepinephrine in the brain, which can help to improve alertness and attention.

What is the generic name of Tanadopa?

DOCARPAMINE is the generic (nonproprietary) name of Tanadopa.

What drug class is Tanadopa in?

Tanadopa belongs to the Catecholamine class. See all Catecholamine drugs at /class/catecholamine.

What development phase is Tanadopa in?

Tanadopa is in Phase 2.

Drug class: All Catecholamine drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing